ACELYRIN (SLRN)

• Market cap: $318M
• 1 day: -0.31%
• 5 days: -10.45%
• 1 month: -32.98%
• 3 months: -35.44%
• 6 months: -21.34%
• Year to date: -60.08%
• 1 year: -59.25%
• 5 years: -86.51%
• 10 years: -86.51%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.

Employees: 130

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

17% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 36

11% more capital invested

Capital invested by funds: $389M [Q2] → $430M (+$41M) [Q3]

9% more funds holding

Funds holding: 112 [Q2] → 122 (+10) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]

1.7% less ownership

Funds ownership: 89.11% [Q2] → 87.41% (-1.7%) [Q3]

43% less call options, than puts

Call options by funds: $154K | Put options by funds: $272K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8 152% upside
• Avg. target: $10.50 231% upside
• High target: $13 310% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

Wells Fargo Derek Archila 44% 1-year accuracy 16 / 36 met price target	310% upside $13	Overweight Maintained	11 Dec 2024
HC Wainwright & Co. Emily Bodnar 15% 1-year accuracy 23 / 150 met price target	152% upside $8	Neutral Reiterated	11 Dec 2024